Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.72M | $34.5M | $75.0M | $136M | $224M | $308M |
| Revenue growth | — | 346.7% | 117.6% | 81.6% | 64.8% | 37.2% |
| Gross profit | -$1.25M | $15.9M | $37.1M | $71.0M | $137M | $196M |
| Gross margin | -16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Operating income | -$47.8M | -$54.2M | -$80.7M | -$109M | -$96.6M | -$104M |
| Operating margin | -619.4% | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Net income | -$53.0M | -$59.9M | -$87.2M | -$106M | -$91.4M | -$95.6M |
| Net margin | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| EPS (diluted) | -$14.47 | -$3.63 | -$1.96 | -$2.24 | -$1.75 | -$1.72 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$48.3M | -$57.3M | -$80.4M | -$108M | -$99.2M | -$49.0M |
| Capital expenditures | $233K | $592K | $2.65M | $25.2M | $4.41M | $9.36M |
| Free cash flow | -$48.6M | -$57.9M | -$83.0M | -$133M | -$104M | -$58.3M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $100M | $304M | $222M | $257M | $334M | $287M |
| Total assets | $126M | $337M | $309M | $405M | $534M | $508M |
| Total liabilities | $65.0M | $69.9M | $112M | $124M | $132M | $142M |
| Long-term debt | $44.4M | $50.0M | $51.2M | $51.3M | $51.5M | $51.6M |
| Shareholders' equity | -$183M | $267M | $197M | $281M | $402M | $366M |
| Retained earnings | -$202M | -$262M | -$349M | -$455M | -$546M | -$642M |
| Shares (wtd avg diluted) | 3.66M | 16.5M | 44.4M | 47.3M | 52.1M | 55.5M |
Every figure is extracted from PROCEPT BioRobotics Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.